WuXi Biologics, a Hong Kong-listed company, is a leading global biologics services provider that offers comprehensive, integrated and highly customizable services. The company offers multinational pharmaceutical and biotechnological companies in the world end-to-end solutions empowering anyone and any company to discover, develop and manufacture biologics from concept to commercial manufacturing. Our services are designed to help our worldwide clients shorten the discovery and development time and lower the cost of biologics.
The ability to rapidly develop biologic products from conception to human clinical trials is an increasingly important aspect of controlling drug development costs and in expediting the drug’s pathway to one day provide critical treatments. Hence, there has been an ... Continued
Is Continuous Biomanufacturing a Good Fit for Your Process? – Continuous Biomanufacturing Implementation – Frequently Asked Questions
We recently finished our Ask the Expert discussion, “Ask the Expert – Implementation of Continuous Manufacturing Strategies for Protein Therapeutics.” During this Ask the Expert session, we covered several common questions related to continuous biomanufacturing, including PAT initiatives, expected timelines, ... Continued
In biomanufacturing, a production scale change is required to either meet the market growth demand or when a product moves from clinical to commercial manufacturing. How that volume is increased depends on whether a scale up or scale out philosophy ... Continued
Answers by: Hang Zhou, Ph.D., Director of Cell Culture Process Development, WuXi Biologics & Sherry Gu, Ph.D, Vice President of CMC Management, WuXi Biologics Introduction There continues to be growing interest in continuous processing of biological therapeutics with the primary driver being reduction of drug ... Continued